Table 1. Observed mean DAS28, mean HAQ-DI and rates of EULAR response in patients continuing on tocilizumab
| Baseline | 6 months | 12 months | 24 months | 36 months | 48 months | |
|---|---|---|---|---|---|---|
| (n=80) | (n=59) | (n=40) | (n=15) | (n=10) | (n=4) | |
| Mean DAS28 (SEM) | 5.4 (0.2) | 3.2 (0.2)* | 2.7 (0.2)* | 2.6 (0.2)* | 2.6 (0.2)* | 2.2 (0.1)** |
| Mean HAQ-DI (SEM) | 1.8 (0.1) | 1.4 (0.1)* | 1.4 (0.1)* | 1.5 (0.2)* | 1.5 (0.3) | 1.2 (0.5)** |
| EULAR response, no. (%) | ||||||
| Good | n/a | 26 (44) | 27 (68) | 11 (73) | 7 (70) | 3 (75) |
| Moderate | n/a | 15 (25) | 8 (20) | 2 (13) | 1 (10) | 0 |
| Nil | n/a | 14 (25) | 5 (13) | 2 (13) | 2 (20) | 1 (25) |
| Not Known | n/a | 4 (7) | 0 | 0 | 0 | 0 |
| DAS28-ESR remission, no. (%) | 0 | 21 (36) | 19 (48) | 11 (73) | 6 (60) | 3 (75) |
*p<0.05 vs. baseline (paired t-test); **p<0.10 vs. baseline (paired t-test).